Eli Lilly and Company LLY, last week, gained the much-anticipated FDA approval for its once-daily oral GLP-1 pill ...
A phase 3 trial of patients with moderate-to-severe TED has shown that subcutaneous injection of Tepezza by way of an on-body ...
The TEPEZZA OBI trial evaluated the safety and efficacy of SC teprotumumab in patients with active TED and proptosis of 3mm or greater from baseline.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results